<?xml version="1.0" encoding="UTF-8"?>
<p>Glasdegib (PF‐04449913) is an oral, small molecule inhibitor of the Hh pathway component SMO.
 <xref rid="ajh25238-bib-0020" ref-type="ref">20</xref>, 
 <xref rid="ajh25238-bib-0021" ref-type="ref">21</xref>, 
 <xref rid="ajh25238-bib-0022" ref-type="ref">22</xref>, 
 <xref rid="ajh25238-bib-0023" ref-type="ref">23</xref>, 
 <xref rid="ajh25238-bib-0024" ref-type="ref">24</xref>, 
 <xref rid="ajh25238-bib-0025" ref-type="ref">25</xref> Glasdegib prevents the translocation of SMO into primary cilia and prevents SMO‐mediated activation of downstream Hh targets.
 <xref rid="ajh25238-bib-0012" ref-type="ref">12</xref>, 
 <xref rid="ajh25238-bib-0023" ref-type="ref">23</xref>, 
 <xref rid="ajh25238-bib-0026" ref-type="ref">26</xref> Previous studies have reported glasdegib inhibition of SMO reduced the expression of key intracellular leukemia stem cell regulators (eg, GLI2) and enhanced cell cycle transit.
 <xref rid="ajh25238-bib-0023" ref-type="ref">23</xref>, 
 <xref rid="ajh25238-bib-0027" ref-type="ref">27</xref> These results and preclinical evidence that Hh inhibition may sensitize cells to cytarabine or azacitidine
 <xref rid="ajh25238-bib-0010" ref-type="ref">10</xref>, 
 <xref rid="ajh25238-bib-0011" ref-type="ref">11</xref>, 
 <xref rid="ajh25238-bib-0014" ref-type="ref">14</xref>, 
 <xref rid="ajh25238-bib-0028" ref-type="ref">28</xref> provided rationale for evaluating glasdegib in combination with chemotherapeutic agents to reduce resistance and leukemic persistence or progression.
</p>
